Boehringer and Tempus AI forge multi-year partnership

German pharmaceutical company Boehringer Ingelheim has entered a multi-year collaboration with Tempus AI (Nasdaq: TEM), aiming to accelerate the development of new cancer therapies by harnessing real-world data and artificial intelligence. 

The deal will see Boehringer Ingelheim tap into Tempus’ extensive de-identified database and advanced analytics platform, Lens, to support its expanding oncology pipeline.

Under the agreement, Boehringer Ingelheim gains access to Tempus’ database, which includes more than eight million research records encompassing molecular, clinical, and imaging data. The Lens platform enables researchers to define and analyze patient cohorts using a range of clinical and molecular filters, or to automate cohort creation with Tempus One, an AI-powered assistant. This approach is designed to guide biomarker development, patient stratification, and the identification of novel drug targets, as well as to generate hypotheses for potential combination therapies.